I. Fichtner, W. Slisow, J. Gill, M. Becker, B. Elbe, T. Hillebrand, M. Bibby (2004)
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.European journal of cancer, 40 2
Sreenath Sharma, D. Bell, J. Settleman, D. Haber (2007)
Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 7
Sae-Won Han, Tae-You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung, S. Im, Y. Kim, J. Lee, D. Heo, Y. Bang, N. Kim (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
J. Spicer, S. Chowdhury, P. Harper (2007)
Targeting novel and established therapies for non-small cell lung cancer.Cancer letters, 250 1
D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William Ince, P. Jänne, T. Januario, David Johnson, P. Klein, V. Miller, M. Ostland, D. Ramies, Dragan Sebisanovic, Jeremy Stinson, Yu Zhang, S. Seshagiri, K. Hillan (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
Kyu-Sik Kim, Ju-yeon Jeong, Young-chul Kim, K. Na, Y. Kim, S. Ahn, S. Baek, Chang-Soo Park, C. Park, Y. Kim, S. Lim, K. Park (2005)
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung CancerClinical Cancer Research, 11
M. Edelman (2005)
An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.Seminars in oncology, 32 6 Suppl 10
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
C. Whiteford, S. Bilke, Braden Greer, Qing-Rong Chen, Till Braunschweig, Nicola Cenacchi, Jun Wei, Malcolm Smith, Peter Houghton, Christopher Morton, C. Reynolds, R. Lock, R. Gorlick, Chand Khanna, Carol Thiele, Mikiko Takikita, D. Catchpoole, Stephen Hewitt, J. Khan (2007)
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.Cancer research, 67 1
F. Cappuzzo, G. Finocchiaro, G. Metro, S. Bartolini, E. Magrini, A. Cancellieri, R. Trisolini, L. Castaldini, G. Tallini, L. Crinò (2006)
Clinical experience with gefitinib: an update.Critical reviews in oncology/hematology, 58 1
A. Borgmann, C. Baldy, A. Stackelberg, B. Beyermann, I. Fichtner, P. Nürnberg, G. Henze (2000)
CHILDHOOD ALL BLASTS RETAIN PHENOTYPIC AND GENOTYPIC CHARACTERISTICS UPON LONG-TERM SERIAL PASSAGE IN NOD/SCID MICEPediatric Hematology and Oncology, 17
(2008)
American Association for Cancer clincancerres.aacrjournals.org Downloaded from
J. Konishi, K. Yamazaki, I. Kinoshita, H. Isobe, S. Ogura, Satoko Sekine, T. Ishida, R. Takashima, Megumi Nakadate, Shyu Nishikawa, Takeshi Hattori, H. Asahina, Mikado Imura, E. Kikuchi, J. Kikuchi, N. Shinagawa, H. Yokouchi, M. Munakata, H. Dosaka-akita, M. Nishimura (2005)
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.Anticancer research, 25 1B
(1999)
Relevance of tumor models for anticancer drug development
M. Tiseo, V. Franciosi, F. Grossi, A. Ardizzoni (2006)
Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?European journal of cancer, 42 1
J. Cutz, J. Guan, J. Bayani, M. Yoshimoto, Hui Xue, M. Sutcliffe, J. English, J. Flint, J. Leriche, J. Yee, J. Squire, P. Gout, S. Lam, Yu-Zhuo Wang (2006)
Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression–Related ChangesClinical Cancer Research, 12
S. Yang, Leah Mechanic, Ping Yang, M. Landi, E. Bowman, J. Wampfler, D. Meerzaman, Kyeong-Man Hong, Felicia Mann, T. Dracheva, J. Fukuoka, W. Travis, N. Caporaso, C. Harris, J. Jen (2005)
Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung CancerClinical Cancer Research, 11
M. Janmaat, F. Kruyt, J. Rodriguez, G. Giaccone (2003)
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 6
Sae-Won Han, P. Hwang, D. Chung, Dong-Wan Kim, S. Im, Y. Kim, Tae-You Kim, D. Heo, Y. Bang, N. Kim (2005)
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancerInternational Journal of Cancer, 113
F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. Franklin, L. Crinò, P. Bunn, M. Varella-Garcia (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Journal of the National Cancer Institute, 97 9
N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer, K. Carroll (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 366
C. Mountain (1997)
Revisions in the International System for Staging Lung Cancer.Chest, 111 6
G. Qiao (2008)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
H. Azim, A. Ganti (2006)
Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?Cancer treatment reviews, 32 8
Y. Xi, A. Riker, Lalita Shevde-Samant, R. Samant, Christopher Morris, E. Gavin, O. Fodstad, J. Ju (2007)
Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts.Cancer genomics & proteomics, 5 1
Takeshi Suzuki, T. Nakagawa, H. Endo, T. Mitsudomi, A. Masuda, Y. Yatabe, T. Sugiura, Takashi Takahashi, T. Hida (2003)
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.Lung cancer, 42 1
E. Massarelli, M. Varella-Garcia, Ximing Tang, A. Xavier, N. Ozburn, Diane Liu, B. Bekele, R. Herbst, I. Wistuba (2007)
KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung CancerClinical Cancer Research, 13
S. Ogino, T. Kawasaki, M. Brahmandam, Liyin Yan, M. Cantor, C. Namgyal, M. Mino‐Kenudson, G. Lauwers, M. Loda, C. Fuchs (2005)
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.The Journal of molecular diagnostics : JMD, 7 3
H. Fiebig, W. Dengler, T. Roth (1999)
Human Tumor Xenografts: Predictivity, Characterization and Discovery of New Anticancer Agents, 54
J. Baselga, C. Arteaga (2005)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
M. Campiglio, A. Locatelli, C. Olgiati, N. Normanno, G. Somenzi, L. Viganò, M. Fumagalli, S. Ménard, L. Gianni (2004)
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression levelJournal of Cellular Physiology, 198
B. Helfrich, D. Raben, M. Varella-Garcia, D. Gustafson, D. Chan, L. Bemis, C. Coldren, A. Baron, C. Zeng, W. Franklin, F. Hirsch, A. Gazdar, J. Minna, P. Bunn (2006)
Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein LevelsClinical Cancer Research, 12
H. Zembutsu, Y. Ohnishi, Y. Daigo, T. Katagiri, T. Kikuchi, S. Kakiuchi, Chiyoko Nishime, K. Hirata, Yusuke Nakamura (2003)
Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839.International journal of oncology, 23 1
(2008)
Cancer Therapy: Preclinical www.aacrjournals.org Clin Cancer Res
P. Steiner, Christopher Joynes, Rajiv Bassi, Su Wang, J. Tonra, Y. Hadari, D. Hicklin (2007)
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor ReceptorClinical Cancer Research, 13
Roman Perez-Soler, Bonnie Kemp, Qing Wu, Li Mao, Jorge Gomez, A. Zeleniuch‐Jacquotte, Herman Yee, J. Lee, J. Jagirdar, Yi-He Ling (2000)
Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 12
H. Sunada, B. Magun, John Mendelsohn, Carol MacLeod (1986)
Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.Proceedings of the National Academy of Sciences of the United States of America, 83 11
E. Gross, M. Kiechle, N. Arnold (2001)
Mutation analysis of p53 in ovarian tumors by DHPLC.Journal of biochemical and biophysical methods, 47 1-2
K. Viktorsson, L. Petris, R. Lewensohn (2005)
The role of p53 in treatment responses of lung cancer.Biochemical and biophysical research communications, 331 3
W. Pao, V. Miller (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
Daniel Jones (2004)
Anticancer drugs: To the rescue?Nature Reviews Drug Discovery, 3
D. Carney (1996)
Chemotherapy in the management of patients with inoperable non-small cell lung cancer.Seminars in oncology, 23 6 Suppl 16
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
P. Maione, C. Gridelli, T. Troiani, F. Ciardiello (2006)
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.The oncologist, 11 3
V. Dangles-Marie, M. Pocard, S. Richon, L. weiswald, F. Assayag, P. Saulnier, J. Judde, J. Janneau, N. Auger, P. Validire, B. Dutrillaux, F. Praz, D. Bellet, M. Poupon (2007)
Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.Cancer research, 67 1
W. Jor, Y. Lee, Wh Sit, Ly Wong, S. Fan, M. Kwan, J. Wan (2007)
Cancer Genomics & Proteomics
F. Sirotnak (2003)
Studies with ZD1839 in preclinical models.Seminars in oncology, 30 1 Suppl 1
D. Raben, B. Helfrich, D. Chan, F. Ciardiello, Limin Zhao, W. Franklin, A. Baron, C. Zeng, T. Johnson, P. Bunn (2005)
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 2 Pt 1
Shyhmin Huang, E. Armstrong, S. Benavente, P. Chinnaiyan, P. Harari (2004)
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)Cancer Research, 64
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
T. Chin, D. Anuar, R. Soo, M. Salto‐Tellez, W. Li, Baidah Ahmad, S. Lee, B. Goh, K. Kawakami, A. Segal, B. Iacopetta, R. Soong (2007)
Detection of epidermal growth factor receptor variations by partially denaturing HPLC.Clinical chemistry, 53 1
Nack Bae, M. Chae, Myung‐Hoon Lee, Kyung Kim, E. Lee, C. Kim, T. Park, S. Han, S. Jheon, T. Jung, J. Park (2007)
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.Cancer genetics and cytogenetics, 173 2
S. Shimizu, T. Mitsudomi (2002)
[Molecular abnormalities in lung cancer].Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 5
F. Morgillo, Ho-Yyoung Lee (2005)
Resistance to epidermal growth factor receptor-targeted therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 8 5
F. Blackhall, M. Ranson, N. Thatcher (2006)
Where next for gefitinib in patients with lung cancer?The Lancet. Oncology, 7 6
Marie-France Poupon, F. Arvelo, A. Goguel, Y. Bourgeois, M. Jacrot, N. Hanania, R. Arriagada, T. Chevalier (1993)
Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.Journal of the National Cancer Institute, 85 24
P. Dutta, A. Maity (2007)
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.Cancer letters, 254 2
V. Miller, M. Zakowski, Gregory Riely, W. Pao, M. Ladanyi, A. Tsao, A. Sandler, R. Herbst, M. Kris, David Johnson (2006)
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
B. Higgins, K. Kolinsky, M. Smith, G. Beck, M. Rashed, Violeta Adames, Michael Linn, E. Wheeldon, L. Gand, H. Birnboeck, G. Hoffmann (2004)
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft modelsAnti-Cancer Drugs, 15
J. Judde, M. Rebucci, N. Vogt, P. Crémoux, A. Livartowski, A. Chapelier, C. Tran‐Perennou, K. Boyé, R. Defrance, M. Poupon, R. Bras-Gonçalves (2007)
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor responseInternational Journal of Cancer, 120
Nicolas Magné, J. Fischel, A. Dubreuil, P. Formento, M. Poupon, Pierre Laurent-Puig, Gérard Milano (2002)
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)British Journal of Cancer, 86
J. Engelman (2007)
The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung CancerClinical Cancer Research, 13
T. Bekaii-Saab, M. Villalona-Calero (2005)
Preclinical experience with docetaxel in gastrointestinal cancers.Seminars in oncology, 32 2 Suppl 4
I. Fichtner, M. Becker, R. Zeisig, A. Sommer (2004)
In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.European journal of cancer, 40 6
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
C. Ozvegy-Laczka, J. Cserepes, N. Elkind, B. Sarkadi (2005)
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 8 1-2
Frances Shepherd (1999)
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?Seminars in oncology, 26 1 Suppl 4
P. Bonomi, L. Buckingham, J. Coon (2007)
Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase InhibitorsClinical Cancer Research, 13
Raffaella Sordella, D. Bell, D. Haber, J. Settleman (2004)
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 305
Samuel Chan, Samuel Chan, W. Gullick, Mark Hill (2006)
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.European journal of cancer, 42 1
R. Rosell, M. Cuello, F. Cecere, M. Santarpia, N. Reguart, E. Felip, M. Taron (2006)
Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are goingCurrent Opinion in Oncology, 18
Sae-Won Han, Tae-You Kim, Y. Jeon, P. Hwang, S. Im, Kyung-Hun Lee, J. Kim, Dong-Wan Kim, D. Heo, N. Kim, D. Chung, Y. Bang (2006)
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt PhosphorylationClinical Cancer Research, 12
D. Bell, T. Lynch, Sara Haserlat, Patricia Harris, R. Okimoto, Brian Brannigan, D. Sgroi, B. Muir, M. Riemenschneider, R. Iacona, A. Krebs, David Johnson, G. Giaccone, R. Herbst, C. Manegold, M. Fukuoka, M. Kris, J. Baselga, J. Ochs, D. Haber (2005)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
F. Cappuzzo, E. Magrini, G. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C. Paties, L. Lombardo, C. Calandri, G. Bellezza, M. Tonato, L. Crinò (2004)
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.Journal of the National Cancer Institute, 96 15
Cancer Epidemiology, Biomarkers and Prevention – Unpaywall
Published: Oct 15, 2008
Access the full text.
Sign up today, get DeepDyve free for 14 days.